Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
Weinblatt, Michael E., Baranauskaite, Asta, Niebrzydowski, Jaroslaw, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Cheong, Soo Yeon, Ghil, Jeehoon, Sokolovic, S., Mekic, M., Prodanovic, N., Gajic, B., Karaselimovic‐Dzambasovic, E., Pojskic, B., Toncheva, A., Dimitar, P., Rodina, L., Geneva‐Popova, M., Staykov, I., Stoilov, R., Podrazilova, L., Mosterova, Z., Simkova, G., Kopackova, J., Stejfova, Z., Vencovsky, J., Urbanova, Z., Janska, L., Galatíkova, D., Stropuviene, S., Sniuoliene, I., Sitek‐Ziolkowska, K., Rell‐Bakalarska, M., Kolasa, R., Daniluk, S., Sliwowska, B., Bartosik‐Twardowska, M., Brzezicki, J., Konieczny, M., Jeka, S., Choe, J., Bae, S., Kang, Y., Prystupa, L., Vyacheslav, Z., Gasanov, I., Yatsyshyn, R., Rekalov, D., Iaremenko, O., Stanislavchuk, M., Tseluyko, V.
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.01.2018)
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.01.2018)
Get full text
Journal Article
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results
Weinblatt, Michael E, Baranauskaite, Asta, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz-Rosiak, Krystyna, Baek, Inyoung, Ghil, Jeehoon
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.06.2018)
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.06.2018)
Get full text
Journal Article
Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study
Weinblatt, Michael E., Genovese, Mark C., Ho, Meilien, Hollis, Sally, Rosiak‐Jedrychowicz, Krystyna, Kavanaugh, Arthur, Millson, David S., Leon, Gustavo, Wang, Millie, Heijde, Désirée
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.12.2014)
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.12.2014)
Get full text
Journal Article
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis
Weinblatt, Michael E., Baranauskaite, Asta, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Baek, Inyoung, Ghil, Jeehoon
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.06.2018)
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.06.2018)
Get full text
Journal Article
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial
Kitas, George D., MD, PhD, FRCP, Abreu, Gabriel, PhD, Jedrychowicz-Rosiak, Krystyna, MD, Miller, Jeffrey L., MD, Nakov, Roumen, MD, PhD, Panfilov, Seva, MD, PhD, Vencovsky, Jiri, MD, PhD, Wang, Millie, MD, Weinblatt, Michael E., MD, White, William B., MD
Published in Journal of the American Society of Hypertension (01.11.2014)
Published in Journal of the American Society of Hypertension (01.11.2014)
Get full text
Journal Article
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
Choe, Jung-Yoon, Prodanovic, Nenad, Niebrzydowski, Jaroslaw, Staykov, Ivan, Dokoupilova, Eva, Baranauskaite, Asta, Yatsyshyn, Roman, Mekic, Mevludin, Porawska, Wieskawa, Ciferska, Hana, Jedrychowicz-Rosiak, Krystyna, Zielinska, Agnieszka, Choi, Jasmine, Rho, Young Hee, Smolen, Josef S
Published in Annals of the rheumatic diseases (01.01.2017)
Published in Annals of the rheumatic diseases (01.01.2017)
Get full text
Journal Article
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
Smolen, Josef S, Choe, Jung-Yoon, Prodanovic, Nenad, Niebrzydowski, Jaroslaw, Staykov, Ivan, Dokoupilova, Eva, Baranauskaite, Asta, Yatsyshyn, Roman, Mekic, Mevludin, Porawska, Wieslawa, Ciferska, Hana, Jedrychowicz-Rosiak, Krystyna, Zielinska, Agnieszka, Lee, Younju, Rho, Young Hee
Published in Annals of the rheumatic diseases (01.02.2018)
Published in Annals of the rheumatic diseases (01.02.2018)
Get full text
Journal Article
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results
Smolen, Josef S, Choe, Jung-Yoon, Prodanovic, Nenad, Niebrzydowski, Jaroslaw, Staykov, Ivan, Dokoupilova, Eva, Baranauskaite, Asta, Yatsyshyn, Roman, Mekic, Mevludin, Porawska, Wieskawa, Ciferska, Hana, Jedrychowicz-Rosiak, Krystyna, Zielinska, Agnieszka, Choi, Jasmine, Rho, Young Hee
Published in Rheumatology (Oxford, England) (01.10.2017)
Published in Rheumatology (Oxford, England) (01.10.2017)
Get full text
Journal Article
Phase III Randomized Study of SB 5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
Weinblatt, Michael E., Baranauskaite, Asta, Niebrzydowski, Jaroslaw, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Cheong, Soo Yeon, Ghil, Jeehoon
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.01.2018)
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.01.2018)
Get full text
Journal Article